Liquid-Chromatographic Determination of Nadolol in Plasma
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We describe a Iiquid-chromatographic procedure for determining nadolol in plasma. After an analog of nadolol is added as internal standard, the plasma sample is passed through a disposable BondElut C18 column. After several column washes, nadolol and the internal standard are eluted with methanol, and the eluate is evaporated and reconstituted with the mobile phase (acetonitrile/water, perchioric acid, and tetramethylammonium hydroxide). An aliquot of the extract is chromatographed on a non-silica resin-base reversed-phase column. The peaks are detected by fluorescence (Xss = 265 nm and Xem = 305). Drug and internal standard are well resolved, and only a few extraneous peaks appear. The standard curve ranges from 10 to 400 g/L. We are using this procedure to determine steady-state concentrations of nado101in patients receiving various dosages of nadolol aloflg with other types of antihypertensive drugs.
Additional Keyphrases: chromatography, reversed-phase . fftj orometry antihypertensive drugs "beta blockers" Nadolol ( Figure 1 ), a new, nonselective beta adrenergic receptor blocker, has been recently approved in North
America for treatment of hypertension and angina pectoris.
Unlike other "beta blockers," it is not metabolized to any great extent in the liver, being excreted largely unchanged in the urine, and it has an unusually long biological halflife, 20-24 h (1). Because nadolol is less able to cross the blood-brain barrier, it is therefore less likely to cause adverse effects such as lassitude and mental depression.
Most of the pharmacokinetic data for this drug have been obtained by a fluorometric procedure (2) in which the drug is oxidized with periodate and the resulting dialdehyde is condensed with o-phenylenediammne to produce a fluorescent product. This procedure has been validated by a gaschromatographic/mass-spectrometric (GC-MS) procedure (3). We have tried to develop a simple chromatographic procedure for the routine monitoring of nadolol concentrations in plasma to check compliance or to monitor accumulation of the drug in patients with diminished renal clearance. were prepared by appropriate dilution with plasma. These standards were stable for six months when stored at -15 #{176}C in 2-mL portions. The stock 1 g/L internal standard solution was prepared by dissolving 100 mg of SQ 23554 in 100 mL of methanol. This solution was stable for three months at 4 #{176}C. For the working solution of internal standard, 10 L of stock solution was diluted to 10 mL with 0.1 mollL sodium acetate when required.
Specimen collection.
Blood was collected from patients who had received nadolol in a constant daily dosage (80, 160, or 320 mg) for at least 14 days. Specimens were collected at four 2-h intervals in blue-capped heparinized Vacutainer Tubes (Becton Dickinson, Orangeburg, NY 10962). The tubes were centrifuged within 2 h of blood collection, and the plasma was collected with Pasteur pipettes and stored in disposable plastic tubes at -15 #{176}C until analyzed.
Sample preparation.
"BondElut C18" 1-mL disposable extraction columns and a "VacElut" system were obtained from Analytichem International
Inc., Harbor
City, CA 90710. The columns were washed under suction twice with methanol, once with 0.1 mollL sodium acetate, and twice with water. Working internal standard (100 /LL) and plasma sample (1.0 mL) were applied to the washed columns. Suction was adjusted so that the liquid passed through the columns in 30-50 s. The columns were washed twice with water, once with methanoL/water (30/70 by vol), and finally with 0.5 mL of pentane. The columns were transferred to labeled 16 x 100 mm disposable glass tubes. We added 1 mL of methanol to each column and centrifuged the tubes to elute the columns. The eluate was evaporated under a stream of nitrogen at 40 #{176}C. The residue in each tube was dissolved in 100 L of mobile phase, and 10 L was injected into the chromatograph.
Chromatography.
The chromatographic separation is performed isocratically at room temperature with a dual-piston packed with 10-zm (av particle diameter) poly(styrenedivinyl benzene) resin (Hamilton Co., Reno, NV 85910). The mobile phase is prepared by mixing 175 mL of acetonitrile, 825 mL of water, 0.5 mL of a 700 g/L solution of perchloric acid, and 0.5 mL of tetramethyl ammonium hydroxide (160 gIL of methanol). It is pumped at 1 mL/min with 8.5 MPa (120 lb/in2) back pressure. We recorded the chromatograms with a Model BD4O recorder (Kipp and Zonen, Bohemia, NY 11716) and integrated the peak areas with a System IV integrator (Spectra Physics, Santa Clara, CA 95051).
Results and Discussion
Nadolol absorbs weakly at 280 nm, where it is difficult to detectin concentrations less than 100 g/L. Detection at 205 nm provides adequate sensitivity, but the many extraneous peaks in chromatograms of plasma extracts obtained with this solid-phase extraction again makes difficult the determination of <100 g of nadolol per liter of plasma. Using the Schotten-Bauman reaction, we obtained a good yield of benzoyl derivative of nadolol with high absorbance at 240 nm. However, on chromatography, the ben.zoyl derivative of nadolol gave a double peak and therefore could not be used. Nadolol oxidized with periodate produces a dialdehyde (2), which we trapped in acidic medium as the 2,4-dinitrophenylhydrazone.
This derivative also had high absorbance at 350 nm, but separating it from extraneous impurities proved difficult.
Determination of nadolol in serum by liquid chromatography with electrochemical detection has been reported (4).
Nadolol has recently been measured by thin-layer chromatography by detection of its native fluorescence (5). Detection of native fluorescence of nadolol in the flow cell of the detector allows sensitive, specific detection of the drug and the internal standard in the extracts of plasma. Pindolol (6) and prenalterol (7) , which have some of the structural features of nadolol, have been measured in plasma by fluorescence detection at Xex = 220 nm. Because the xenon lamp of our fluorescence detector does not allow excitation at less than 260 nm, we cannot comment as to whether the sensitivity or specificity of detection would improve at lower Only a few extraneous peaks appear and there is no interference from any possible peak from a previous injection, even after 20 injections of plasma extracts. The peaks for nadolol and the internal standard are symmetrical and clearly resolved. The ratio of peak areas or of peak heights of nadolollinternal standard is linearly related to nadolol concentration over the range 10-400 .tgfL, and the standard curve passes through the origin. The procedure allows quantitative determination of as little as 10 .tg of nadolol per liter. The sensitivity of the procedure may be further increased by dissolving the dried residue in a smaller volume of mobile phase (<bOO ML).
Because of the presence of hydroxyl groups, nadolol is quite polar. Its extraction from plasma for GC-MS is tedious, involving lyophilization of the acidic aqueous extract obtained by back-extracting the butyl acetate extract of plasma. The present extraction procedure is convenient, involves a minimum of glassware, and has a 85-95% yield. The analytical recovery of the drug is lessened if the mixture of plasma and internal standard passes through the column in less than 30 s. There is no change in the ratio of drug to internal standard after extracting an aqueous mixture of the two compounds by the present procedure. SQ 23554, being an isomer of nadolol, is an ideal internal standard for this determination.
The plasma extract obmined by the present procedure is also suitable for analysis by GC with the use of a nitrogen-selective detector (8) . Analysis of plasma supplemented with 100 ig of nadolol per liter showed a within-batch CV of 5.3% (n = 11, mean = 100.9 g/L)
and a between-batch CV of 8.3% (n = 10, mean = 100.6 g/L). Even with only a few patients at each dosage, it can be seen that this procedure allows good discrimination between doses. (Because of the small number of patients studied, we did not calculate confidence intervals for each mean value.) Some of the patients were also receiving hydrochlorthiazide and hydralazine, these and other commonly prescribed antihypertensive drugs do not interfere with this assay for nadolol.
We conclude that this simple chromatographic procedure is suitable for routine determination of therapeutic concentrations of nadolol in plasma.
